Persistent Asset Partners Ltd Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP

Persistent Asset Partners Ltd purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,208 shares of the specialty pharmaceutical company’s stock, valued at approximately $660,000.

A number of other large investors also recently modified their holdings of ANIP. Rubric Capital Management LP increased its stake in shares of ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after purchasing an additional 200,998 shares during the period. Teacher Retirement System of Texas grew its holdings in ANI Pharmaceuticals by 3,156.3% during the second quarter. Teacher Retirement System of Texas now owns 147,380 shares of the specialty pharmaceutical company’s stock worth $9,617,000 after acquiring an additional 142,854 shares during the period. Global Alpha Capital Management Ltd. raised its position in ANI Pharmaceuticals by 17.2% in the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after acquiring an additional 126,500 shares in the last quarter. First Trust Advisors LP boosted its position in shares of ANI Pharmaceuticals by 128.1% during the 2nd quarter. First Trust Advisors LP now owns 81,214 shares of the specialty pharmaceutical company’s stock valued at $5,299,000 after purchasing an additional 45,613 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in shares of ANI Pharmaceuticals by 363.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 58,027 shares of the specialty pharmaceutical company’s stock worth $5,315,000 after purchasing an additional 45,516 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ANIP shares. Barclays assumed coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $103.43.

Insider Activity

In related news, Director Renee P. Tannenbaum sold 1,800 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the transaction, the director owned 25,157 shares in the company, valued at $2,041,490.55. This trade represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,622 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $82.40, for a total value of $133,652.80. Following the sale, the senior vice president directly owned 58,564 shares of the company’s stock, valued at $4,825,673.60. This represents a 2.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 4,322 shares of company stock worth $354,816. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.4%

ANIP stock opened at $78.10 on Friday. The company has a market cap of $1.75 billion, a PE ratio of 47.91 and a beta of 0.50. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals, Inc. has a twelve month low of $54.10 and a twelve month high of $99.50. The business’s 50-day simple moving average is $80.87 and its 200 day simple moving average is $86.24.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.